Table 2.
Correlation of relative EM with clinical characteristics
| Items | Relative EM, median (IQR) | Z value | P value |
|---|---|---|---|
| Age | − 0.976 | 0.329 | |
| < 60 years | 7.7 (4.4–9.7) | ||
| ≥ 60 years | 7.8 (4.9–13.1) | ||
| Gender | − 0.842 | 0.400 | |
| Male | 6.8 (4.7–10.3) | ||
| Female | 8.8 (4.7–13.4) | ||
| Live metastases | − 1.521 | 0.128 | |
| Single | 10.1 (6.3–13.4) | ||
| Multiple | 6.8 (4.5–10.3) | ||
| Head of pancreas | − 1.584 | 0.113 | |
| No | 8.8 (5.0–11.0) | ||
| Yes | 5.5 (4.0–9.8) | ||
| Body of pancreas | − 0.596 | 0.551 | |
| No | 7.7 (4.4–11.0) | ||
| Yes | 7.8 (5.2–10.4) | ||
| Cauda of pancreas | − 1.978 | 0.048 | |
| No | 5.7 (4.3–9.5) | ||
| Yes | 9.3 (5.1–13.1) | ||
| Number of extrahepatic metastases | − 0.618 | 0.536 | |
| 0–1 | 8.1 (5.1–10.3) | ||
| > 1 | 5.6 (4.3–11.1) | ||
| Enterocoelia metastasis | − 0.502 | 0.616 | |
| No | 7.9 (4.3–10.6) | ||
| Yes | 7.8 (5.0–10.8) | ||
| Lymph gland metastasis | − 1.883 | 0.060 | |
| No | 8.1 (4.9–10.9) | ||
| Yes | 4.5 (2.7–7.3) | ||
| Skeleton metastasis | − 2. 092 | 0.036 | |
| No | 8.6 (4.9–11.1) | ||
| Yes | 4.7 (3.4–7.1) | ||
| Lung metastasis | − 2.059 | 0.040 | |
| No | 7.7 (4.5–10.6) | ||
| Yes | 14.0 (10.1–NR) | ||
| No extrahepatic metastases | − 0.812 | 0.417 | |
| No | 7.3 (4.5–10.6) | ||
| Yes | 9.0 (5.0–12.8) | ||
| Size of liver metastasis | − 2.707 | 0.007 | |
| < 3 cm | 5.2 (4.3–9.9) | ||
| ≥ 3 cm | 9.3 (7.2–11.6) | ||
| AG | − 0.479 | 0.632 | |
| No | 8.8 (5.3–10.4) | ||
| Yes | 5.7 (4.4–11.9) | ||
| Other GEM-based regimens | − 0.275 | 0.783 | |
| No | 8.0 (4.7–10.3) | ||
| Yes | 7.8 (4.7–11.6) | ||
| Folfirinox | − 0.463 | 0.644 | |
| No | 7.8 (4.9–10.7) | ||
| Yes | 8.8 (2.4–12.9) | ||
| Others | − 0.573 | 0.567 | |
| No | 7.8 (4.6–10.5) | ||
| Yes | 7.2 (4.8–14.1) |
EM Elastic modulus, IQR Interquartile range, NR Not reported, GEM Gemcitabine